Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold retractors that are minimally invasive surgical device solutions. The company has a strategic collaboration with Medtronic for the development and commercialization of BackBeat CNT for the treatment of hypertension in pacemaker-indicated patients; and a strategic partnership with Terumo Corporation for the development and commercialization of Virtue SAB for the treatment of artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.

Orchestra BioMed Holdings, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

NEW HOPE, PA., AUG. 20, 2026 (GLOBE NEWSWIRE) -- ORCHESTRA BIOMED HOLDINGS, INC. (NASDAQ: OBIO, ORCHESTRA BIOMED OR THE COMPANY), A BIOMEDICAL COMPANY ACCELERATING HIGH-IMPACT TECHNOLOGIES TO PATIENTS THROUGH RISK-REWARD SHARING PARTNERSHIPS, TODAY ANNOUNCED THAT CHAIRMAN AND CEO DAVID HOCHMAN WILL PRESENT AT THE WELLS FARGO 21ST ANNUAL HEALTHCARE CONFERENCE ON THURSDAY, SEPT. 10, 2026 AT 1:30PM ET AND WILL ALSO HOST ONE-ON-ONE MEETINGS WITH INVESTORS THAT DAY AND ON WEDNESDAY, SEPT. 9.

ORCHESTRA BIOMED TO PARTICIPATE IN THE WELLS FARGO 21ST ANNUAL HEALTHCARE CONFERENCE

NEW HOPE, PA., JUNE 29, 2026 (GLOBE NEWSWIRE) -- ORCHESTRA BIOMED HOLDINGS, INC. (NASDAQ: OBIO) (ORCHESTRA BIOMED OR THE COMPANY), A BIOMEDICAL COMPANY ACCELERATING HIGH-IMPACT TECHNOLOGIES TO PATIENTS THROUGH RISK-REWARD SHARING PARTNERSHIPS, ANNOUNCED TODAY THAT IT HAS JOINED THE BROAD-MARKET RUSSELL 3000 INDEX AND THE SMALL-CAP RUSSELL 2000 INDEX AT THE CONCLUSION OF THE 2026 RUSSELL INDEXES RECONSTITUTION, EFFECTIVE AFTER THE U.S. MARKET CLOSE ON JUNE 26, 2026.

ORCHESTRA BIOMED JOINS RUSSELL 3000 AND RUSSELL 2000 INDEXES

NEW HOPE, PA., JUNE 02, 2026 (GLOBE NEWSWIRE) -- ORCHESTRA BIOMED HOLDINGS, INC. (NASDAQ: OBIO) (ORCHESTRA BIOMED OR THE COMPANY), A BIOMEDICAL COMPANY ACCELERATING HIGH-IMPACT TECHNOLOGIES TO PATIENTS THROUGH STRATEGIC PARTNERSHIPS WITH MARKET-LEADING GLOBAL MEDICAL DEVICE COMPANIES, REPORTED TODAY THAT, ON JUNE 1, 2026, THE COMPENSATION COMMITTEE OF THE ORCHESTRA BIOMED BOARD OF DIRECTORS GRANTED STOCK OPTIONS TO PURCHASE AN AGGREGATE OF 85,500 SHARES OF THE COMPANY'S COMMON STOCK TO FIVE NEWLY HIRED EMPLOYEES. THE AWARDS WERE GRANTED PURSUANT TO THE ORCHESTRA BIOMED HOLDINGS, INC. 2025 NEW HIRE INDUCEMENT PLAN AS AN INDUCEMENT MATERIAL TO EACH NEW EMPLOYEE ENTERING EMPLOYMENT WITH ORCHESTRA BIOMED, IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4). THE STOCK OPTIONS GRANTED TO EACH NEW EMPLOYEE WILL VEST OVER A FOUR-YEAR PERIOD.

ORCHESTRA BIOMED ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

NEW HOPE, PA., MAY 19, 2026 (GLOBE NEWSWIRE) -- ORCHESTRA BIOMED HOLDINGS, INC. (NASDAQ: OBIO, ORCHESTRA BIOMED OR THE COMPANY), A BIOMEDICAL COMPANY ACCELERATING HIGH-IMPACT TECHNOLOGIES TO PATIENTS THROUGH RISK-REWARD SHARING PARTNERSHIPS, TODAY ANNOUNCED THAT COMPANY MANAGEMENT WILL BE PARTICIPATING IN THE JEFFERIES GLOBAL HEALTHCARE CONFERENCE.

ORCHESTRA BIOMED TO PARTICIPATE IN THE JEFFERIES GLOBAL HEALTHCARE CONFERENCE

NEW HOPE, PA., MAY 12, 2026 (GLOBE NEWSWIRE) -- ORCHESTRA BIOMED HOLDINGS, INC. (NASDAQ: OBIO, ORCHESTRA BIOMED OR THE COMPANY), A BIOMEDICAL COMPANY ACCELERATING HIGH-IMPACT TECHNOLOGIES TO PATIENTS THROUGH RISK-REWARD SHARING PARTNERSHIPS, TODAY ANNOUNCED FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2026, AND PROVIDED A BUSINESS UPDATE HIGHLIGHTING MOMENTUM ACROSS THE COMPANY'S PIVOTAL-STAGE PROGRAMS FOR ATRIOVENTRICULAR INTERVAL MODULATION (AVIM) THERAPY AND VIRTUE SIROLIMUS ANGIOINFUSIONBALLOON (VIRTUE SAB) SUPPORTED BY THE COMPANY'S STRONG BALANCE SHEET.

ORCHESTRA BIOMED REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND HIGHLIGHTS RECENT BUSINESS UPDATES

NEW HOPE, PA., MAY 12, 2026 (GLOBE NEWSWIRE) -- ORCHESTRA BIOMED HOLDINGS, INC. (NASDAQ: OBIO) (ORCHESTRA BIOMED OR THE COMPANY), A BIOMEDICAL COMPANY ACCELERATING HIGH-IMPACT TECHNOLOGIES TO PATIENTS THROUGH STRATEGIC PARTNERSHIPS WITH MARKET-LEADING GLOBAL MEDICAL DEVICE COMPANIES, TODAY ANNOUNCED AN UPDATE TO THE OVERALL CLINICAL AND REGULATORY TIMELINE FOR THE BACKBEAT TRIAL EVALUATING ATRIOVENTRICULAR INTERVAL MODULATION THERAPY (AVIM THERAPY) IN PACEMAKER-INDICATED PATIENTS WITH UNCONTROLLED HYPERTENSION DESPITE MEDICATIONS. THE COMPANY IS TARGETING COMPLETION OF ENROLLMENT BY THE END OF THE THIRD QUARTER OF 2026. FURTHER, THE COMPANY AND MEDTRONIC, ITS STRATEGIC COLLABORATOR FOR THE BACKBEAT TRIAL AND THE COMMERCIALIZATION OF AVIM THERAPY FOR THE TREATMENT OF UNCONTROLLED HYPERTENSION IN PATIENTS INDICATED FOR A PACEMAKER, PLAN TO SUBMIT THE PRIMARY ENDPOINT DATA FOR A LATE-BREAKING CLINICAL TRIAL PRESENTATION AT A MAJOR CARDIOVASCULAR CONFERENCE IN THE SECOND QUARTER OF 2027. LASTLY, ASSUMING PRIMARY SAFETY AND EFFICACY ENDPOINTS ARE MET, MEDTRONIC PLANS TO SUBMIT A MARKETING APPLICATION FOR FDA APPROVAL AFTER PRIMARY ENDPOINT DATA ANALYSES AND REPORTS ARE COMPLETE, AND SUBSEQUENTLY TO PURSUE GLOBAL REGULATORY APPROVALS.

ORCHESTRA BIOMED TARGETING BACKBEAT TRIAL ENROLLMENT COMPLETION BY END OF Q3 2026 AND DATA PRESENTATION IN Q2 2027

NEW HOPE, PA., MAY 06, 2026 (GLOBE NEWSWIRE) -- ORCHESTRA BIOMED HOLDINGS, INC. (NASDAQ: OBIO) (ORCHESTRA BIOMED OR THE COMPANY), A BIOMEDICAL COMPANY ACCELERATING HIGH-IMPACT TECHNOLOGIES TO PATIENTS THROUGH STRATEGIC PARTNERSHIPS WITH MARKET-LEADING GLOBAL MEDICAL DEVICE COMPANIES, TODAY ANNOUNCED THE RECEIPT OF A $15 MILLION PAYMENT FROM LIGAND PHARMACEUTICALS INCORPORATED (NASDAQ: LGND) PURSUANT TO THE PREVIOUSLY DISCLOSED REVENUE PARTICIPATION RIGHT PURCHASE AND SALE AGREEMENT (THE ROYALTY PURCHASE AGREEMENT). THE PAYMENT COMPLETES A SCHEDULED TRANCHE UNDER THE AGREEMENT AND REFLECTS LIGAND'S CONTINUED STRATEGIC CAPITAL SUPPORT OF ORCHESTRA BIOMED'S LATE-STAGE CARDIOVASCULAR PROGRAMS, AVIM THERAPY AND VIRTUE SAB, WHICH ARE BOTH BEING EVALUATED IN ONGOING RANDOMIZED, CONTROLLED PIVOTAL TRIALS.

ORCHESTRA BIOMED RECEIVES $15 MILLION INVESTMENT FROM LIGAND UNDER PREVIOUSLY ANNOUNCED STRATEGIC FINANCING AGREEMENT

PAYMENT FULFILLS PREVIOUSLY DISCLOSED FUNDING COMMITMENT OF $20 MILLION AND SUPPORTS PLANNED COMPLETION OF THE BACKBEAT GLOBAL PIVOTAL TRIAL (BACKBEAT TRIAL) EVALUATING ATRIOVENTRICULAR INTERVAL MODULATION THERAPY (AVIM THERAPY) IN PATIENTS WITH UNCONTROLLED HYPERTENSION AND AN INDICATION FOR A PACEMAKER AS PART OF THE STRATEGIC COLLABORATION BETWEEN ORCHESTRA BIOMED AND MEDTRONIC THIS PAYMENT, TOGETHER WITH $15 MILLION RECEIVED FROM LIGANDAND ANNOUNCED SEPARATELY, REPRESENTS A TOTAL OF $35 MILLION IN STRATEGIC CAPITAL RECEIVED UNDER PREVIOUSLY DISCLOSED AGREEMENTS NEW HOPE, PA., MAY 06, 2026 (GLOBE NEWSWIRE) -- ORCHESTRA BIOMED HOLDINGS, INC. (NASDAQ: OBIO) (ORCHESTRA BIOMED OR THE COMPANY), A BIOMEDICAL COMPANY ACCELERATING HIGH-IMPACT TECHNOLOGIES TO PATIENTS THROUGH STRATEGIC PARTNERSHIPS WITH MARKET-LEADING GLOBAL MEDICAL DEVICE COMPANIES, TODAY ANNOUNCED THE RECEIPT OF A $20 MILLION INVESTMENT FROM MEDTRONIC, PLC.

ORCHESTRA BIOMED RECEIVES $20 MILLION PAYMENT FROM MEDTRONIC UNDER PREVIOUSLY ANNOUNCED FINANCING AGREEMENT

ATRIOVENTRICULAR INTERVAL MODULATION (AVIM) THERAPY FOOD AND DRUG ADMINISTRATION (FDA) BREAKTHROUGH DEVICE DESIGNATIONS SPAN THE BROADER POPULATION OF PATIENTS WITH UNCONTROLLED HYPERTENSION DESPITE MEDICATION AT INCREASED CARDIOVASCULAR RISK AND THE SPECIFIC PACEMAKER-INDICATED POPULATION BEING EVALUATED IN THE BACKBEAT TRIAL THE ADDRESSABLE U.S. PATIENT POPULATION FOR AVIM THERAPY, BASED ON THE INDICATIONS FOR USE SPECIFIED IN ITS BREAKTHROUGH DEVICE DESIGNATIONS, COMPRISES OVER 7.7 MILLION ADULTS WITH HYPERTENSION DESPITE MEDICATION BREAKTHROUGH DEVICE DESIGNATION SUPPORTS FAVORABLE REIMBURSEMENT PATHWAYS, INCLUDING POTENTIAL ELIGIBILITY FOR NEW TECHNOLOGY ADD-ON PAYMENT (NTAP) AND TRANSITIONAL PASS-THROUGH (TPT) PAYMENT, WHICH CAN FACILITATE BROADER, MORE TIMELY PATIENT ACCESS AND PROVIDER ADOPTION NEW HOPE, PA., APRIL 30, 2026 (GLOBE NEWSWIRE) -- ORCHESTRA BIOMED HOLDINGS, INC. (NASDAQ: OBIO) (ORCHESTRA BIOMED OR THE COMPANY), A BIOMEDICAL COMPANY ACCELERATING HIGH-IMPACT TECHNOLOGIES TO PATIENTS THROUGH STRATEGIC PARTNERSHIPS WITH MARKET-LEADING GLOBAL MEDICAL DEVICE COMPANIES, TODAY ANNOUNCED THAT THE FDA HAS GRANTED A SECOND BREAKTHROUGH DEVICE DESIGNATION (BDD) FOR AVIM THERAPY SPECIFIC TO PATIENTS WITH UNCONTROLLED HYPERTENSION DESPITE THE USE OF ANTI-HYPERTENSIVE MEDICATIONS, AND AN INDICATION FOR A PACEMAKER.

FDA GRANTS ORCHESTRA BIOMED ADDITIONAL BREAKTHROUGH DEVICE DESIGNATION FOR AVIM THERAPY

NEW HOPE, PA., APRIL 23, 2026 (GLOBE NEWSWIRE) -- ORCHESTRA BIOMED HOLDINGS, INC. (NASDAQ: OBIO) (ORCHESTRA BIOMED OR THE COMPANY), A BIOMEDICAL COMPANY ACCELERATING HIGH-IMPACT TECHNOLOGIES TO PATIENTS THROUGH STRATEGIC PARTNERSHIPS WITH MARKET-LEADING GLOBAL MEDICAL DEVICE COMPANIES, TODAY ANNOUNCED TWO AVIM THERAPY PRESENTATIONS AT THE HEART RHYTHM SOCIETY (HRS) 2026 ANNUAL MEETING.

Orchestra BioMed Holdings, Inc.

OBIO

Price

Financial Reports

No items found.

Press Releases

Orchestra BioMed Holdings, Inc.

OBIO.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

OBIO